Dexamethasone 0.7 mg Implant for the Treatment of Recalcitrant Radiation Maculopathy after Proton Radiotherapy for Carcinoma of the Maxillary Sinus
DOI:
https://doi.org/10.12974/2309-6136.2014.02.01.7Keywords:
Corticosteroids, cystoid macular edema, intravitreal implant, macular edema, Ozurdex, radiation retinopathy, steroids.Abstract
Purpose: To report the efficacy of dexamethasone 0.7 mg intravitreal implant in recalcitrant radiation retinopathy. Method: Retrospective case report of a single case describing successful treatment of radiation retinopathy with dexamethasone 0.7 mg intravitreal implant following multiple failed attempts with both bevacizumab and focal laser. Results: After the first injection of 0.7 mg dexamethasone the best corrected visual acuity (BCVA) improved from 20/400 to 20/250 and central macular thickness (CMT) decreased. BCVA continued to improve after a second injection to 20/125 and remained stable through the third and fourth injection at 20/150, respectively. The intraocular pressure remained within normal limits. Conclusion: 0.7 mg dexamethasone implant showed benefit in a recalcitrant case of radiation retinopathy.
References
Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy—clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond) 1991; 5: 239–251. http://dx.doi.org/10.1038/eye.1991.39
Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999; 106: 1571–1577; discussion 1577–1578. http://dx.doi.org/10.1016/S0161-6420(99)90455-4
Lane AM, Kim IK, Gragoudas ES. Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol 2011; 129: 1127–1130. http://dx.doi.org/10.1001/archophthalmol.2011.228
Sutter FK, Gillies MC. Intravitreal triamcinolone for radiationinduced macular edema. Arch Ophthalmol 2003; 121: 1491-3. http://dx.doi.org/10.1001/archopht.121.10.1491
Shields JA, Shields CL. Management of posterior uveal melanoma. Atlas of Intraocular Tumors. Philadelphia: Lippincott Williams & Wilkins; 1999: 113–140.
Shields JA, Shields CL. Management of posterior uveal melanoma. Intraocular Tumors. A Text and Atlas. Philadelphia: WB Saunders; 1992: 171–206.
Shields CL, Shields JA, Gunduz K, Freire JE, Mercado G. Radiation therapy for uveal malignant melanoma. Ophthalmic Surg Lasers 1998; 29: 397–409.
Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology 1992; 99: 1278–1285. http://dx.doi.org/10.1016/S0161-6420(92)31832-9
Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy foruveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000; 118: 1219–1228. http://dx.doi.org/10.1001/archopht.118.9.1219
Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology 2001; 108: 348–366. http://dx.doi.org/10.1016/S0161-6420(00)00526-1
Seddon JM, Gragoudas ES, Polivogianis L, Hsieh CC, Egan KM, Goitein M, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmology 1986; 93: 666–674. http://dx.doi.org/10.1016/S0161-6420(86)33700-X
Kinyoun JL, Zamber RW, Lawrence BS, Barlow WE, Arnold AM. Photocoagulation treatment for clinically significant radiation macular oedema. Br J Ophthalmol 1995; 79: 144– 149. http://dx.doi.org/10.1136/bjo.79.2.144
Hykin PG, Shields CL, Shields JA, Arevalo JF. The efficacy of focal laser therapy in radiation-induced macular edema. Ophthalmology 1998; 105: 1425–1429. http://dx.doi.org/10.1016/S0161-6420(98)98023-X
Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008; 28: 964–968. http://dx.doi.org/10.1097/IAE.0b013e3181706302
Mason JO 3rd, Albert MA Jr, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007; 27: 903–907. http://dx.doi.org/10.1097/IAE.0b013e31806e6042
Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol 2007; 125: 751–756. http://dx.doi.org/10.1001/archopht.125.6.751
Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008; 70: 974–977. http://dx.doi.org/10.1016/j.ijrobp.2007.11.045
Bakri SJ, Larson RA. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy. Semin Ophthalmol 2013 Nov 19.
[Epub ahead of print] http://dx.doi.org/10.3109/08820538.2013.847110
Bakri SJ, Beer PM: Photodynamic therapy for maculopathy due to radiation retinopathy. Eye 2005; 19: 795–799. http://dx.doi.org/10.1038/sj.eye.6701637
Lee SC, Song JH, Chung EJ, Kwon OW. Photodynamic therapy of subretinal neovascularization in radiation retinopathy. Eye (Lond) 2004; 18: 745–746. http://dx.doi.org/10.1038/sj.eye.6700736
Gupta P, Meisenberg B, Amin P, Pomeranz H. Radiation retinopathy: the role of pentoxifylline. Retina 2001; 21: 545– 547. http://dx.doi.org/10.1097/00006982-200110000-00026
Gall N, Leiba H, Handzel R, Pe’er J. Severe radiation retinopathy and optic neuropathy after brachytherapy for choroidal melanoma, treated by hyperbaric oxygen. Eye (Lond) 2007; 21: 1010–1012. http://dx.doi.org/10.1038/sj.eye.6702820
Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation induced macular edema. Arch Ophthalmol 2003; 121: 1491– 1493. http://dx.doi.org/10.1001/archopht.121.10.1491
Shields CL, Demirci H, Dai V, Marr BP, Mashayekhi A, Materin MA, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 2005; 25: 868–874. http://dx.doi.org/10.1097/00006982-200510000-00009
Baillif S, Maschi C, Gastaud P, Caujolle JP. Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma. Retina 2013; 33: 1784-1790. http://dx.doi.org/10.1097/IAE.0b013e31829234fa
Russo A, Teresio A, Uva M, Faro S, Franco L, Sanfilippo M, et al. Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol 2012; 3: 71-6. http://dx.doi.org/10.1159/000337144
Gillies MC. Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema. Doc Ophthalmol 1999; 97: 251-60. http://dx.doi.org/10.1023/A:1002196930726
Sivaprasad S, McCluskey P, Lightman S. Intravitrealsteroids in the management of macular oedema. ActaOphthalmol Scand 2006; 84: 722–733. http://dx.doi.org/10.1111/j.1600-0420.2006.00698.x
Reibaldi M, Russo A, Zagari M, Toro M, Grande De V, Cifalino V, et al. Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg. Case Rep Ophthalmol 2012; 3: 30-4. http://dx.doi.org/10.1159/000336273
Goldfien A. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology. 6th ed. London, United Kingdom: Prentice Hall International 1995; pp. 592–607.
Herrero-Vanell R, Cardillo JA, Kuppermann BD. Clinical applications for the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011; 5: 139–146.
Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289–296. http://dx.doi.org/10.1001/archophthalmol.2010.21
Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048–1054. http://dx.doi.org/10.1016/j.ajo.2008.12.033
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453–2460. http://dx.doi.org/10.1016/j.ophtha.2011.05.014
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545–553. http://dx.doi.org/10.1001/archophthalmol.2010.339
Shimura M, Nakazaw T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145: 854–861. http://dx.doi.org/10.1016/j.ajo.2007.12.031
Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 12: 57-61. http://dx.doi.org/10.1001/archopht.121.1.57
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538. http://dx.doi.org/10.1016/j.ophtha.2006.02.065
Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol 2006; 17: 235–244. http://dx.doi.org/10.1097/01.icu.0000193107.00089.ee
London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011; 28: 351-366. http://dx.doi.org/10.1007/s12325-011-0019-z
